Keymed Biosciences (FRA:64Z) Current Deferred Taxes Liabilities: € Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:64Z Keymed Biosciences Inc FRA:64Z
53 GF Score
Price €7.90
GF Value €16.65
! 4 Warning Signs
View Full Analysis

What is Keymed Biosciences Current Deferred Taxes Liabilities?

Keymed Biosciences FRA:64Z +0.64% 53 Current Deferred Taxes Liabilities is € Mil as of Jun. 2026. GuruFocus rates FRA:64Z with a GF Score™ of 53/100 and a GF Value™ of €16.65. The stock has 4 warning signs investors should review.

Current Deferred Taxes Liabilities represent future tax liabilities, resulting from temporary differences between book (accounting) value of assets and liabilities and their tax value, or timing differences between the recognition of gains and losses in financial statements and their recognition in a tax computation. Deferred tax liabilities generally arise where tax relief is provided in advance of an accounting expense, or income is accrued but not taxed until received.

Keymed Biosciences's current deferred tax liabilities for the quarter that ended in Jun. 2026 was € Mil.

Keymed Biosciences Current Deferred Taxes Liabilities Related Terms

Keymed Biosciences Current Deferred Taxes Liabilities Historical Data

* Premium members only.

The historical data trend for Keymed Biosciences's Current Deferred Taxes Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Keymed Biosciences Current Deferred Taxes Liabilities Chart

Keymed Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Taxes Liabilities
Get a 7-Day Free Trial - - - - -

Keymed Biosciences Semi-Annual Data
Jun20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Current Deferred Taxes Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -
FRA:64Z
53GF Score
Keymed Biosciences Inc FRA:64Z
Current Deferred Taxes Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Taxes Liabilities of € Mil mean?
Keymed Biosciences (FRA:64Z) has a Current Deferred Taxes Liabilities of € Mil as of Jun. 2026. Current Deferred Tax Liabilities records the total amount of taxes due for the period but not yet paid. View historical data on Keymed Biosciences and its competitors.
Is Keymed Biosciences' Current Deferred Taxes Liabilities too high?
Keymed Biosciences' current Current Deferred Taxes Liabilities is € Mil. Overall, Keymed Biosciences has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does Keymed Biosciences' Current Deferred Taxes Liabilities compare to VRTX and REGN?
Keymed Biosciences' Current Deferred Taxes Liabilities of € Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Taxes Liabilities for a Biotechnology company?
A good Current Deferred Taxes Liabilities depends on the Biotechnology industry context. However, Current Deferred Taxes Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Taxes Liabilities mean?
A high Current Deferred Taxes Liabilities can signal that a stock is expensive relative to its fundamentals. Current Deferred Tax Liabilities records the total amount of taxes due for the period but not yet paid. View historical data on Keymed Biosciences and its competitors. Keymed Biosciences's current Current Deferred Taxes Liabilities is € Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Keymed Biosciences stock overvalued right now?
Keymed Biosciences (FRA:64Z) has a current Current Deferred Taxes Liabilities of € Mil. The stock's GF Value™ is €16.65, compared to a current price of €7.90 — trading 52.6% below its estimated fair value. The current Current Deferred Taxes Liabilities is € Mil. Keymed Biosciences' overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Taxes Liabilities calculated?
Current Deferred Taxes Liabilities is calculated from a company's financial statements. For Keymed Biosciences (FRA:64Z), the current Current Deferred Taxes Liabilities is € Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Keymed Biosciences (FRA:64Z) Overvalued in 2026?

Based on GuruFocus' analysis, Keymed Biosciences stock appears to be undervalued. The current stock price of €7.90 is trading 52.6% below its estimated GF Value™ of €16.65.

Key valuation signals for FRA:64Z:

  • Current Deferred Taxes Liabilities: € Mil
  • GF Value™: €16.65 vs. price of €7.90 (52.6% below fair value)
  • GF Score™: 53/100 with 4 warning signs

No single metric tells the full story. See the FRA:64Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Keymed Biosciences Business Description

Other Exchanges 02162:Hong Kong
Address No. 669 Fenghuang Road, Shuangliu District, Chengdu, Sichuan, CHN, 610219
Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. Its clinical-stage drug candidates include CM310, CM326, CM313, and CM336 among others. The company is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it generates a majority of its revenue from overseas markets and the rest from Mainland China.
53GF Score

Get the complete analysis for FRA:64Z

Current Deferred Taxes Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.90
Price
€16.65
GF Value